Get the Stockscreener App
0.00
100.00%
-4.36
After Hours:
4.60
4.60
+
Adverum Biotechnologies Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$4.36
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$96.26M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
0.00
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$4.3785
52-Week Range:
$0.00
$5.75
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
0.00 | 96.26M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Adverum Biotechnologies (NASDAQ:ADVM) Lowered to “Strong Sell” Rating by Wall Street Zen - Defense World
Market Catalysts: Why hedge funds are buying Adverum Biotechnologies Inc stockJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Hedge Fund and Insider Trading News: Cathie Wood, Michael Burry, Renaissance Technologies, Mason Capital, Millennium Management, Adverum Biotechnologies Inc (ADVM), MGM Resorts International (MGM), and More - Insider Monkey
Adverum Biotechnologies, Inc.(NasdaqCM: ADVM) dropped from S&P TMI Index - marketscreener.com
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - The Malaysian Reserve
Eli Lilly (LLY) Completes Acquisition of Adverum Biotechnologies - GuruFocus
Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies - Nasdaq
Lilly completes tender offer for Adverum Biotechnologies - Investing.com
Monday’s Insider Moves: Adverum Execs Lead Buys, Diamondback Sale Tops - Investing.com Australia
Adverum Biotechnologies Stock (ADVM) Opinions on Lilly Acquisition - Quiver Quantitative
Lilly completes tender offer for Adverum Biotechnologies By Investing.com - Investing.com UK
Lilly completes Adverum acquisition for $3.56 per share plus CVRs - StreetInsider
Adverum Biotechnologies (NASDAQ:ADVM) CEO Buys $47,000.40 in Stock - MarketBeat
Insider Buying: Laurent Fischer Acquires Shares of Adverum Biote - GuruFocus
Soparkar Peter, Adverum Biotechnologies COO, buys $211k in shares By Investing.com - Investing.com Canada
Adverum biotechnologies CEO Fischer buys shares worth $553916 By Investing.com - Investing.com Canada
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock - Defense World
Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock - MarketBeat
What analysts say about Adverum Biotechnologies Inc stockEarnings Per Share Trends & Try Our Free Strategy Builder Now - earlytimes.in
Owner Leonard Sells 524,560 ($2.2M) Of Adverum Biotechnologies Inc [ADVM] - TradingView
Adverum Reminds Stockholders to Tender Their Shares Into the Offer by Lilly - 富途牛牛
LUNA Surges 20% in a Day Amid Ongoing Terra Network Upgrade - Bitget
Why retail traders accumulate Adverum Biotechnologies Inc. (AVU0) stockWeekly Profit Report & Advanced Swing Trade Entry Alerts - Newser
Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells 222,925 Shares of Stock - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Sells 51,961 Shares - MarketBeat
Adverum Biotechnologies Releases Promising Phase 2 Trial Data - TipRanks
Adverum Biotechnologies, Inc. Announces Two-Year Data from LUNA Phase 2 Trial - TradingView — Track All Markets
How Adverum Biotechnologies Inc. (AVU0) stock reacts to stronger dollarJuly 2025 Highlights & Growth Oriented Trade Recommendations - Newser
Why Adverum Biotechnologies Inc. (AVU0) stock trades below fair valueMarket Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Is Adverum Biotechnologies Inc. (AVU0) stock resilient in recession scenariosQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Leonard of Adverum Bio sells $2.4m in shares By Investing.com - Investing.com Canada
Owner Leonard Sells 574,886 ($2.4M) Of Adverum Biotechnologies Inc [ADVM] - TradingView
Is Adverum Biotechnologies Inc. (AVU0) stock undervalued by metricsJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Published on: 2025-12-02 05:06:35 - Newser
What technical patterns form on Adverum Biotechnologies Inc. (AVU0) stock charts - Newser
Will Adverum Biotechnologies Inc. (AVU0) stock return to pre crash levelsMarket Growth Review & Consistent Profit Trading Strategies - Newser
How Adverum Biotechnologies Inc. (AVU0) stock performs in volatility spikesQuarterly Market Review & Precise Trade Entry Recommendations - Newser
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns - Investing.com Canada
Adverum reminds stockholders to tender their shares into the offer by Lilly - marketscreener.com
Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnolo - GuruFocus
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns By Investing.com - Investing.com South Africa
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biote - The National Law Review
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Adverum Biotechnologies Faces Lease Termination Notice - TipRanks
Adverum Biotechnologies IncARE-NC Region No. 21 LLC terminates certain lease agreement with Adverum BiotechnologiesSEC filing - MarketScreener
[8-K] Adverum Biotechnologies, Inc. Reports Material Event | ADVM SEC FilingForm 8-K - Stock Titan
Lilly strengthens gene therapy portfolio with MeiraGTx and Adverum deals - Drug Discovery News
Chart overlay techniques for tracking Adverum Biotechnologies Inc.2025 Price Targets & Low Risk Growth Stock Ideas - newser.com
Is Adverum Biotechnologies Inc. stock cheap compared to fundamentals2025 Retail Activity & Weekly High Momentum Picks - newser.com
Why Adverum Biotechnologies Inc. stock remains on watchlistsJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adverum Biotechnologies Inc Stock (ADVM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rubinstein Linda M | CHIEF FINANCIAL OFFICER |
Dec 09 '25 |
Option Exercise |
4.20 |
48,750 |
204,750 |
61,150 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
Dec 08 '25 |
Buy |
4.31 |
117,614 |
506,916 |
201,513 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
Dec 05 '25 |
Buy |
4.24 |
11,085 |
47,000 |
83,899 |
| Soparkar Peter | CHIEF OPERATING OFFICER |
Dec 05 '25 |
Buy |
4.22 |
50,000 |
211,000 |
80,189 |
| Leonard Braden Michael | 10% Owner |
Dec 04 '25 |
Sale |
4.19 |
524,560 |
2,200,372 |
1,958,080 |
| Leonard Braden Michael | 10% Owner |
Dec 01 '25 |
Sale |
4.20 |
300,000 |
1,260,000 |
2,757,526 |
| Leonard Braden Michael | 10% Owner |
Dec 03 '25 |
Sale |
4.17 |
222,925 |
929,597 |
2,428,640 |
| Leonard Braden Michael | 10% Owner |
Dec 02 '25 |
Sale |
4.20 |
51,961 |
218,236 |
2,705,565 |
| Soparkar Peter | CHIEF OPERATING OFFICER |
May 15 '25 |
Sale |
2.00 |
2,960 |
5,920 |
39,154 |
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER |
May 15 '25 |
Sale |
2.00 |
924 |
1,848 |
13,768 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):